全球领先的数字病理软件提供商Proscia近日宣布,成功在C+轮融资中募集到900万美元,使得本轮总融资额达到了4600万美元。本轮融资由Highline Capital Management和Triangle Peak Partners共同领投,包括Alpha Intelligence Capital、Scale Venture Partners以及Hitachi Ventures在内的现有投资者也参与了投资。
此次募集的资金将主要用于推动Proscia的商业增长,同时深化其在生命科学和诊断实验室领域的人工智能应用程序的研发。Proscia的AI驱动病理学云平台已经在业界建立了显著的影响力,其创新技术有望进一步革新病理学研究和诊断的效率与精度。
Proscia的首席执行官表示:“我们非常感谢投资者对Proscia的持续支持和信任。这笔资金将使我们能够加速实现我们的愿景,即通过人工智能技术改变病理学的未来,提高全球患者的诊断质量和治疗效果。”
随着数字化病理学的快速发展,Proscia的解决方案正在全球范围内得到广泛应用。新注入的资金将有助于公司扩大市场覆盖面,同时加强其在AI病理学领域的领导地位,为医疗健康行业带来更为精准和高效的服务。
英语如下:
**News Title:** “Proscia, an AI Pathology Platform, Raises $9 Million in C+ Funding Round to Accelerate Technology’s Role in Medical Diagnostics”
**Keywords:** Proscia, AI Pathology, $9 Million Funding
**News Content:**
**Title:** AI-Powered Pathology Cloud Platform Proscia Secures $9 Million in C+ Funding Round to Fuel Technology Development and Commercial Expansion
Proscia, a global leader in digital pathology software, recently announced that it has raised $9 million in its C+ funding round, bringing the total funds raised in this round to $46 million. The round was co-led by Highline Capital Management and Triangle Peak Partners, with participation from existing investors, including Alpha Intelligence Capital, Scale Venture Partners, and Hitachi Ventures.
The proceeds from this funding will predominantly be used to drive Proscia’s commercial growth and deepen its investment in artificial intelligence (AI) applications for life sciences and diagnostic laboratories. Proscia’s AI-driven pathology cloud platform has already made a significant impact in the industry, with its innovative technology poised to further revolutionize the efficiency and accuracy of pathology research and diagnostics.
“Proscia’s CEO remarked, “We are deeply grateful for our investors’ continued support and trust. This funding will enable us to accelerate our vision of transforming the future of pathology through AI, enhancing diagnostic quality and patient outcomes worldwide.”
As digital pathology gains momentum, Proscia’s solutions are being increasingly adopted globally. The new influx of capital will support the company’s expansion into new markets and reinforce its leadership in AI pathology, contributing to more precise and efficient services for the healthcare industry.
【来源】https://venturebeat.com/ai/proscias-46m-series-c-propels-ai-driven-pathology-into-the-mainstream/
Views: 1